Exchange Traded Concepts LLC Decreases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM)

Exchange Traded Concepts LLC lessened its position in HUTCHMED (China) Limited (NASDAQ:HCM) by 21.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,131 shares of the company’s stock after selling 2,820 shares during the quarter. Exchange Traded Concepts LLC’s holdings in HUTCHMED were worth $198,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its position in HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after buying an additional 564 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in HUTCHMED by 9.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock worth $226,000 after buying an additional 1,168 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in HUTCHMED by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 57,010 shares of the company’s stock worth $958,000 after buying an additional 1,388 shares in the last quarter. Russell Investments Group Ltd. lifted its position in HUTCHMED by 70.5% during the first quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company’s stock worth $304,000 after buying an additional 7,515 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in HUTCHMED in the second quarter valued at $213,000. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Stock Down 0.2 %

Shares of NASDAQ HCM opened at $20.85 on Tuesday. HUTCHMED has a twelve month low of $11.93 and a twelve month high of $21.92. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock has a fifty day simple moving average of $18.39 and a 200-day simple moving average of $18.49.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. StockNews.com downgraded HUTCHMED from a “buy” rating to a “hold” rating in a research report on Thursday, July 18th. The Goldman Sachs Group lifted their target price on HUTCHMED from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Thursday, August 1st.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.